Data from a phase 3 study indicated the microbiota-based live biotherapeutic RBL was safe and efficacious for recurrent CDI prevention in immunocompromised patients.

Exposure to antibiotics following FMT may lead to recurrent CDI, suggesting the need for modified strategies to prevent recurrent CDI in some patients.